De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
LSL Pharma Group Balans Gezondheid
Financiële gezondheid criteriumcontroles 4/6
LSL Pharma Group has a total shareholder equity of CA$19.5M and total debt of CA$11.2M, which brings its debt-to-equity ratio to 57.4%. Its total assets and total liabilities are CA$37.0M and CA$17.5M respectively.
Belangrijke informatie
57.4%
Verhouding schuld/eigen vermogen
CA$11.17m
Schuld
| Rente dekkingsratio | n/a |
| Contant | CA$289.00k |
| Aandelen | CA$19.47m |
| Totaal verplichtingen | CA$17.48m |
| Totaal activa | CA$36.95m |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: LSL's short term assets (CA$9.9M) exceed its short term liabilities (CA$9.3M).
Langlopende schulden: LSL's short term assets (CA$9.9M) exceed its long term liabilities (CA$8.2M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: LSL's net debt to equity ratio (55.9%) is considered high.
Schuld verminderen: Insufficient data to determine if LSL's debt to equity ratio has reduced over the past 5 years.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: LSL has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Voorspelling contante baan: LSL is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.